<p>Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?</p>-Reference-Cited by-同舟云学术

Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?

Published:2020-09 Issue: Volume:Volume 13 Page:3243-3254
ISSN:1178-6973
Container-title:Infection and Drug Resistance
language:en
Short-container-title:IDR

Author:

Al-Ani Mena,Elemam Noha Mousaad^ORCID,Hundt Jennifer Elisabeth,Maghazachi Azzam A^ORCID

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology

Reference139 articles.

1. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

2. The COVID‐19 epidemic

3. A pneumonia outbreak associated with a new coronavirus of probable bat origin

4. GISAID Global Initiative on Sharing All Inﬂuenza Data. Phylogeny of SARS-like betacoronaviruses including novelcoronavirus (nCoV). Available from: https://nextstrain.org/groups/blab/sars-like-cov.

5. A novel coronavirus outbreak of global health concern

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NK Cell Levels Correlate with Disease Activity in Patients with Multiple Sclerosis on Ocrelizumab/Rituximab Therapy;Pharmaceuticals;2024-01-23

2. A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments;Biomedicines;2023-09-08

3. Novel potential pharmacological applications of dimethyl fumarate—an overview and update;Frontiers in Pharmacology;2023-09-07

4. Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design;Biomedicines;2023-05-08

5. Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders;European Journal of Pediatrics;2023-04-19